On November 4, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is reported lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month (Press release, Genprex, NOV 4, 2019, View Source [SID1234550265]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer. The following are preventive actions that may lower the risk of getting lung cancer:

Do not smoke, or if you smoke, then quit smoking – Tobacco, cigarettes and other smoking products all increase the risk of lung cancer.
Reduce your exposure to secondhand smoke – People who inhale secondhand smoke are exposed to the same cancer-causing agents as smokers, but at a reduced amount.
Reduce your exposure to radon – Have your home tested and treated for high radon levels, which can cause lung cancer.
Know your family’s history with lung cancer – If you have a family history of lung cancer, then you are at an increased risk of getting lung cancer.
According to the World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver, prostate or skin cancers, and lung cancer is one of the most common types of cancer. Each year, there are more than 2 million new lung cancer cases and 1.7 million deaths from lung cancer worldwide.

The American Cancer Society’s 2019 report states that each year in the United States there are more than 228,000 new cases of lung cancer and more than 142,000 deaths from lung cancer. NSCLC represents 84 percent of all lung cancers and has a 23 percent five-year relative survival rate. However, according to the National Cancer Institute, 57 percent of lung cancer diagnoses are distant, or have metastasized, and the five-year relative survival rate for distant diagnoses is less than 5 percent.

LUNGevity Foundation points out that 10-15 percent of lung cancer cases are in never smokers, and it is possible to get lung cancer even if you have never smoked.

Genprex is working to put an end to this deadly disease. The company is developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC).